Equities research analysts expect that La Jolla Pharmaceutical (NASDAQ:LJPC) will report ($1.82) earnings per share (EPS) for the current quarter, Zacks reports. Four analysts have issued estimates for La Jolla Pharmaceutical’s earnings. The highest EPS estimate is ($1.54) and the lowest is ($1.97). La Jolla Pharmaceutical reported earnings of ($1.74) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 4.6%. The firm is expected to issue its next earnings results on Thursday, February 28th.

According to Zacks, analysts expect that La Jolla Pharmaceutical will report full-year earnings of ($7.97) per share for the current financial year, with EPS estimates ranging from ($8.11) to ($7.70). For the next financial year, analysts forecast that the business will post earnings of ($4.50) per share, with EPS estimates ranging from ($6.03) to ($1.51). Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that follow La Jolla Pharmaceutical.

La Jolla Pharmaceutical (NASDAQ:LJPC) last announced its quarterly earnings results on Wednesday, October 24th. The biopharmaceutical company reported ($1.93) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($2.01) by $0.08. The company had revenue of $3.47 million for the quarter, compared to analyst estimates of $3.38 million.

LJPC has been the topic of several research analyst reports. Zacks Investment Research upgraded shares of La Jolla Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Tuesday, September 18th. ValuEngine lowered shares of La Jolla Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Monday, October 8th. Jefferies Financial Group dropped their price objective on shares of La Jolla Pharmaceutical from $23.00 to $22.00 and set an “underperform” rating on the stock in a research note on Thursday, August 9th. HC Wainwright restated a “buy” rating and issued a $53.00 price objective on shares of La Jolla Pharmaceutical in a research note on Friday, September 7th. Finally, SunTrust Banks set a $45.00 price objective on shares of La Jolla Pharmaceutical and gave the company a “buy” rating in a research note on Thursday, August 9th. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $51.00.

Shares of NASDAQ:LJPC opened at $13.95 on Tuesday. La Jolla Pharmaceutical has a 12 month low of $13.50 and a 12 month high of $41.36.

A number of hedge funds and other institutional investors have recently bought and sold shares of LJPC. Metropolitan Life Insurance Co. NY increased its stake in La Jolla Pharmaceutical by 42.5% in the second quarter. Metropolitan Life Insurance Co. NY now owns 8,699 shares of the biopharmaceutical company’s stock valued at $254,000 after purchasing an additional 2,594 shares during the period. First Midwest Bank Trust Division acquired a new position in La Jolla Pharmaceutical in the second quarter valued at $279,000. MetLife Investment Advisors LLC increased its stake in La Jolla Pharmaceutical by 42.8% in the second quarter. MetLife Investment Advisors LLC now owns 12,259 shares of the biopharmaceutical company’s stock valued at $358,000 after purchasing an additional 3,674 shares during the period. State Board of Administration of Florida Retirement System increased its stake in La Jolla Pharmaceutical by 27.2% in the second quarter. State Board of Administration of Florida Retirement System now owns 14,575 shares of the biopharmaceutical company’s stock valued at $425,000 after purchasing an additional 3,120 shares during the period. Finally, Employees Retirement System of Texas acquired a new position in La Jolla Pharmaceutical in the second quarter valued at $525,000.

La Jolla Pharmaceutical Company Profile

La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. It offers GIAPREZA, an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock.

See Also: Why investors pay attention to retained earnings

Get a free copy of the Zacks research report on La Jolla Pharmaceutical (LJPC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for La Jolla Pharmaceutical (NASDAQ:LJPC)

Receive News & Ratings for La Jolla Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.